NorthWest Biotherapeutics Inc (NWBO)

[gnawkz]

Overview of Observed Overall Survival for all Stage IV cancers being treated by DCVax-Direct:

1. Soft Tissue Sarcoma ... 5 Year Observed Survival Rate - N/A
2. Pancreatic Cancer ... 5 Year Survival Rate - 1%
3. Neuroendocrine Tumors ... Help Look For?
4. Non-Small Cell Lung Cancer ... 5 Year Observed Survival Rate - 1%
5. Melanoma ... 5 Year Observed Survival Rate - 15% to 20%
6. Colorectal Cancer ... 5 Year Observed Survival Rate - 10%
7. Ovarian Cancer ... 5 Year Observed Survival Rate - 17% to 69% depending on type of Ovarian Cancer

Looking at the observed 5-year survival rates above, I think it becomes clear that some of these Stage IV cancers will be best served using a RECIST or equivalent primary endpoint to ensure trial does not keep going for 5+ years.

For cancers where the 5-Year observed survival is non-existent, I think it is possible NWBO could move forward with a PFS / OS trial instead.

The purpose of bringing this up to attention is to give everyone an idea of the flexibility that NWBO has when pursuing Phase II. When making a decision about which type of cancer to pursue in the next clinical trial, those factors will probably not only include the shrinkage of existing tumors, but also OS and PFS.